StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2022, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jun 2022 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html for the full story. http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Wed, 01 Jun 2022 08:00:00 -0400 ACTI O.00613976 Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html for the full story. http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Wed, 01 Jun 2022 08:00:00 -0400 ACTI O.00613976 Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html for the full story. http://www.streetinsider.com/Press+Releases/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Wed, 01 Jun 2022 08:00:00 -0400 ACTI O.00613976 Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html for the full story. http://www.streetinsider.com/Globe+Newswire/Successful+completion+of+the+first+stage+of+the+phase+IIa+clinical+trial+of+naptumomab+in+combination+with+docetaxel+and+the+study+is+now+enrolling+into+the+second+stage/20158271.html Wed, 01 Jun 2022 08:00:00 -0400 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Press+Releases/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 Annual General Meeting of Active Biotech AB http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html for the full story. http://www.streetinsider.com/Globe+Newswire/Annual+General+Meeting+of+Active+Biotech+AB/20103192.html Thu, 19 May 2022 11:00:00 -0400 A.26626296 ACTI O.00613976 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Press+Releases/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html for the full story. http://www.streetinsider.com/Globe+Newswire/FDA+grants+Orphan+Drug+Designation+for+tasquinimod+in+myelofibrosis/20096170.html Wed, 18 May 2022 09:00:00 -0400 A.06822034 ACTI O.00613976 O.20026344 Annual Report 2021 Active Biotech AB (publ) http://www.streetinsider.com/Press+Releases/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html for the full story. http://www.streetinsider.com/Press+Releases/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html Thu, 28 Apr 2022 03:40:00 -0400 ACTI Annual Report 2021 Active Biotech AB (publ) http://www.streetinsider.com/Globe+Newswire/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html for the full story. http://www.streetinsider.com/Globe+Newswire/Annual+Report+2021+Active+Biotech+AB+%28publ%29/19973592.html Thu, 28 Apr 2022 03:40:00 -0400 ACTI Active Biotech strengthens the patent protection for laquinimod in eye disorders http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html for the full story. http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Tue, 26 Apr 2022 02:30:00 -0400 A.03718595 ACTI Active Biotech strengthens the patent protection for laquinimod in eye disorders http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html for the full story. http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Tue, 26 Apr 2022 02:30:00 -0400 A.03718595 ACTI Active Biotech strengthens the patent protection for laquinimod in eye disorders http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html for the full story. http://www.streetinsider.com/Press+Releases/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Tue, 26 Apr 2022 02:30:00 -0400 A.03718595 ACTI Active Biotech strengthens the patent protection for laquinimod in eye disorders http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html for the full story. http://www.streetinsider.com/Globe+Newswire/Active+Biotech+strengthens+the+patent+protection+for+laquinimod+in+eye+disorders/19956664.html Tue, 26 Apr 2022 02:30:00 -0400 A.03718595 ACTI Active Biotech Interim Report Q1 2022 http://www.streetinsider.com/Press+Releases/Active+Biotech+Interim+Report+Q1+2022/19938161.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Active+Biotech+Interim+Report+Q1+2022/19938161.html for the full story. http://www.streetinsider.com/Press+Releases/Active+Biotech+Interim+Report+Q1+2022/19938161.html Thu, 21 Apr 2022 02:30:00 -0400 ACTI